330 related articles for article (PubMed ID: 21574259)
1. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
2. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
3. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
[TBL] [Abstract][Full Text] [Related]
4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
5. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
[TBL] [Abstract][Full Text] [Related]
6. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
7. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
8. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
Shen J; Pinkus GS; Deshpande V; Cibas ES
Am J Clin Pathol; 2009 Apr; 131(4):516-23. PubMed ID: 19289587
[TBL] [Abstract][Full Text] [Related]
10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
12. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
Lee AF; Gown AM; Churg A
Am J Surg Pathol; 2013 Mar; 37(3):421-6. PubMed ID: 23108021
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
14. The significance of detecting glucose transporter 1 and calretinin in serous effusions to differentiate between carcinoma cells and reactive mesothelial cells.
Lv M; Cha N; Zou YF; Leng JH; Hao YY; Wang S
Diagn Cytopathol; 2021 Jul; 49(7):811-816. PubMed ID: 33818924
[TBL] [Abstract][Full Text] [Related]
15. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
Dejmek A
Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
[TBL] [Abstract][Full Text] [Related]
16. A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.
Yan J; Wei Q; Jian W; Liu J; Tang H; Ge J; Zhou J; Zhao T
Int J Clin Exp Pathol; 2014; 7(9):5810-8. PubMed ID: 25337222
[TBL] [Abstract][Full Text] [Related]
17. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
19. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
